文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

西维来司他通过抑制PI3K/AKT通路保护脓毒症大鼠急性肾损伤

[Sivelestat protects acute kidney injury by inhibiting the PI3K/AKT pathway in septic rats].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论脓毒症大鼠模型中,西维来司他50或100 mg/kg尾静脉注射可减轻肾损伤并抑制PI3K/AKT通路,高剂量效果更优,但48小时生存率无显著差异。

该研究将64只雄性Wistar大鼠随机分为假手术组、盲肠结扎穿孔(CLP)脓毒症组、低剂量西维来司他组(SL组,CLP后12小时和24小时尾静脉注射50 mg/kg)和高剂量组(SH组,同时间点尾静脉注射100 mg/kg),每组16只。结果显示,与CLP组相比,SL组和SH组48小时生存率无显著差异(68.75%、75.00% vs. 56.25%,均P>0.05),但肾小管损伤评分、胶原容积分数、血清KIM-1、IL-1β、IL-6、TNF-α、NE水平及肾组织p-PI3K/PI3K、p-AKT/AKT、NF-κB p65、NE蛋白表达均显著降低(均P<0.05),且SH组上述指标进一步低于SL组(均P<0.05)。作者认为西维来司他可改善脓毒症所致急性肾损伤,机制可能与抑制PI3K/AKT通路有关,高剂量效果更好。

要点

  • 脓毒症大鼠CLP后12小时和24小时尾静脉注射西维来司他50 mg/kg(SL组)或100 mg/kg(SH组),48小时生存率分别为68.75%、75.00%,与CLP组56.25%相比无显著差异(均P>0.05)。
  • 与CLP组相比,SL组和SH组肾小管损伤评分显著降低[2(1,2)、1(1,1) vs. 2(2,3),均P<0.05],胶原容积分数显著降低[(22.36±0.86)%、(18.74±1.05)% vs. (58.38±0.79)%,均P<0.05]。
  • 与CLP组相比,SL组和SH组血清KIM-1、IL-1β、IL-6、TNF-α、NE水平均显著降低(均P<0.05),且SH组进一步低于SL组(均P<0.05)。
  • 与CLP组相比,SL组和SH组肾组织p-PI3K/PI3K、p-AKT/AKT、NF-κB p65/GAPDH、NE/GAPDH蛋白表达均显著降低(均P<0.05),SH组进一步低于SL组(均P<0.05)。
  • 作者认为西维来司他可改善脓毒症所致急性肾损伤,机制可能与抑制PI3K/AKT通路有关,高剂量效果更好。

适用人群与场景

  • 雄性Wistar大鼠,采用随机数字表法分为假手术组、CLP脓毒症组、SL组和SH组,每组16只,共64只。

处置流程与药物剂量

  • SL组:CLP后12小时和24小时经尾静脉注射西维来司他50 mg/kg。
  • SH组:CLP后12小时和24小时经尾静脉注射西维来司他100 mg/kg。

研究设计与关键结果

  • 研究类型:动物实验;64只雄性Wistar大鼠随机分为假手术组、CLP组、SL组(50 mg/kg西维来司他)和SH组(100 mg/kg西维来司他),每组16只。
  • 与假手术组相比,CLP组48小时生存率显著降低,肾组织出现肾小管上皮细胞和刷状缘脱落、管型形成、部分肾小管萎缩、肾小球充血、肾间质炎性细胞浸润、肾小管损伤评分增高、肾间质纤维化明显、胶原容积分数增高,血清KIM-1、IL-1β、IL-6、TNF-α、NE水平显著升高,肾组织p-PI3K/PI3K、p-AKT/AKT、NF-κB p65、NE蛋白表达显著增高。
  • 与CLP组相比,SL组和SH组48小时生存率无显著差异(68.75%、75.00% vs. 56.25%,均P>0.05)。
  • 与CLP组相比,SL组和SH组肾小管损伤评分显著降低[2(1,2)、1(1,1) vs. 2(2,3),均P<0.05],胶原容积分数显著降低[(22.36±0.86)%、(18.74±1.05)% vs. (58.38±0.79)%,均P<0.05]。
  • 与CLP组相比,SL组和SH组血清KIM-1显著降低[(145.03±8.88)ng/L、(117.58±7.02)ng/L vs. (158.22±12.00)ng/L,均P<0.05],IL-1β显著降低[(108.32±9.00)ng/L、(92.98±8.06)ng/L vs. (133.78±8.48)ng/L,均P<0.05],IL-6显著降低[(124.33±10.11)ng/L、(115.42±8.17)ng/L vs. (165.19±5.70)ng/L,均P<0.05],TNF-α显著降低[(321.56±19.29)ng/L、(289.68±21.57)ng/L vs. (424.88±22.76)ng/L,均P<0.05],NE显著降低[(93.84±9.14)mol/L、(75.01±10.56)mol/L vs. (113.45±6.39)mol/L,均P<0.
  • 与CLP组相比,SL组和SH组肾组织p-PI3K/PI3K显著降低(0.93±0.06、0.67±0.04 vs. 1.27±0.08,均P<0.05),p-AKT/AKT显著降低(0.78±0.09、0.47±0.05 vs. 0.96±0.12,均P<0.05),NF-κB p65/GAPDH显著降低(1.43±0.13、0.85±0.08 vs. 1.88±0.17,均P<0.05),NE/GAPDH显著降低(1.45±0.06、0.91±0.04 vs. 1.71±0.08,均P<0.05)。
  • 与CLP组相比,SL组和SH组肾组织p-PI3K阳性表达面积显著降低[(13.36±1.84)%、(8.03±1.12)% vs. (21.56±1.20)%,均P<0.05],p-AKT阳性表达面积显著降低[(21.57±0.91)%、(15.21±2.76)% vs. (30.81±2.12)%,均P<0.05],NF-κB p65阳性表达面积显著降低[(25.17±1.38)%、(17.07±2.11)% vs. (37.85±2.50)%,均P<0.05]。
  • SH组血清炎症因子水平、肾组织PI3K/AKT通路相关蛋白、NF-κB p65、NE蛋白表达水平及p-PI3K、p-AKT、NF-κB p65阳性面积等指标均进一步低于SL组(均P<0.05)。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠CLP脓毒症模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为西维来司他可改善脓毒症所致急性肾损伤,机制可能与抑制PI3K/AKT通路有关,高剂量效果更好;该结论来自脓毒症大鼠模型,原文未据此给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the protective effect of sivelestat (SV) against sepsis-induced acute kidney injury (AKI) and its molecular mechanism.

METHODS: According to the random number table method, 64 male Wistar rats were divided into sham operation group (Sham group), sepsis due to cecal ligation and puncture group (CLP group), low dose of SV treatment group (SL group, 50 mg/kg SV was injected into the tail vein at 12 hours and 24 hours after CLP), and high dose of SV treatment group (SH group, 100 mg/kg SV was injected into the tail vein at 12 hours and 24 hours after CLP), with 16 rats in each group. 48 hours after CLP, the 48-hour survival of rats were recorded, all rats were sacrificed and samples were harvested. Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of kidney injury molecule-1 (KIM-1), interleukins (IL-1β, IL-6), tumor necrosis factor-α (TNF-α) and neutrophil elastase (NE). Hematoxylin-eosin (HE) staining was used to observe histopathological changes and assess renal tubule injury score. Masson staining was used to detect the collagen volume fraction (CVF) of kidney tissue. Western blotting was used to detect the protein expressions of phosphatidylinositol 3-kinase (PI3K), phosphorylation PI3K (p-PI3K), protein kinase B (AKT), phosphorylation AKT (p-AKT), nuclear factor-κB p65 (NF-κB p65) and NE. The protein expressions of p-PI3K, p-AKT, NF-κB p65 were detected by immunohistochemistry.

RESULTS: Compared with Sham group, the 48-hour survival rate of CLP group was significantly reduced. Histopathological results showed that large tubular epithelial cells and brush margins were shed, tubular casts were formed, some tubular atrophy, glomerular hyperemia, renal interstitial inflammatory cell infiltration and increased renal tubular injury score. Renal interstitial fibrosis was obvious and CVF increased. The levels of KIM-1, IL-1β, IL-6, TNF-α and NE in serum were significantly elevated in the CLP group. The proteins expression of inflammatory pathway-related p-PI3K/PI3K, p-AKT/AKT, NF-κB p65 and NE were significantly increased in kidney tissue. It suggested that septic rats had renal injury and the PI3K/AKT inflammatory pathway was activated. Compared with CLP group, there was no significant difference in 48-hour survival in SL group and SH group (68.75%, 75.00% vs. 56.25%, both P > 0.05), but kidney injury was significantly relieved. Specifically: renal tubular injury score and CVF significantly decreased [tubular injury score: 2 (1, 2), 1 (1, 1) vs. 2 (2, 3); CVF: (22.36±0.86)%, (18.74±1.05)% vs. (58.38±0.79)%, all P < 0.05]; the serum levels of KIM-1, IL-1β, IL-6, TNF-α and NE also decreased significantly [KIM-1 (ng/L): 145.03±8.88, 117.58±7.02 vs. 158.22±12.00; IL-1β (ng/L): 108.32±9.00, 92.98±8.06 vs. 133.78±8.48; IL-6 (ng/L): 124.33±10.11, 115.42±8.17 vs. 165.19±5.70; TNF-α (ng/L): 321.56±19.29, 289.68±21.57 vs. 424.88±22.76, NE (mol/L): 93.84±9.14, 75.01±10.56 vs. 113.45±6.39, all P < 0.05]; the proteins expression of inflammatory pathway-related p-PI3K/PI3K, p-AKT/AKT, NF-κB p65 and NE were significantly decreased (p-PI3K/PI3K: 0.93±0.06, 0.67±0.04 vs. 1.27±0.08; p-AKT/AKT: 0.78±0.09, 0.47±0.05 vs. 0.96±0.12; NF-κB p65/GAPDH: 1.43±0.13, 0.85±0.08 vs. 1.88±0.17; NE/GAPDH: 1.45±0.06, 0.91±0.04 vs. 1.71±0.08, all P < 0.05), the positive expressions of p-PI3K, p-AKT and NF-κB p65 in kidney tissue were decreased [p-PI3K positive expression area: (13.36±1.84)%, (8.03±1.12)% vs. (21.56±1.20)%; p-AKT positive expression area: (21.57±0.91)%, (15.21±2.76)% vs. (30.81±2.12)%; NF-κB p65 positive expression area: (25.17±1.38)%, (17.07±2.11)% vs. (37.85±2.50)%, all P < 0.05]. Serum inflammatory factor level, and PI3K/AKT pathway related protein, NF-κB p65, NE protein expression level and p-PI3K, p-AKT, NF-κB p65 positive area and other indicators in renal tissue in SH group were further lower than those in SL group (all P < 0.05).

CONCLUSIONS: SV can ameliorate sepsis-induced AKI. The mechanism may be related to the inhibition of PI3K/AKT pathway, and high dose of SV has better efficacy.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Ding Q, Wang Y, Yang C, et al. [Sivelestat protects acute kidney injury by inhibiting the PI3K/AKT pathway in septic rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 36916337. doi:10.3760/cma.j.cn121430-20220303-00201

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。